The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, ...
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, ...
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and Feb...
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, ...
LOS ANGELES, June 27, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 6, 2024 deadline to file a lead plaintiff motion in the class action fi...
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, ...
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, ...
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, ...
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, ...